13F HOLDINGS REPORT
Atlas Venture Life Science Advisors, LLC
Quarter ended Q1 2024 · Filed May 6, 2024 · Accession 0001104659-24-057096
Total Value
$1.08B
Positions
16
Other Managers
0
Confidential Omitted
No
Holdings (16)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Dyne Therapeutics, Inc. | DYN | 8,020,136 | $227.7M | 21.01% |
| 2 | Kymera Therapeutics, Inc. | KYMR | 5,377,362 | $216.2M | 19.95% |
| 3 | Disc Medicine, Inc. | IRON | 2,287,233 | $142.4M | 13.14% |
| 4 | Day One Biopharmaceuticals, Inc. | DAWN | 6,430,257 | $106.2M | 9.80% |
| 5 | Third Harmonic Bio, Inc. | 88427A107 | 10,907,859 | $103.0M | 9.50% |
| 6 | Korro Bio, Inc. | KRRO | 1,119,292 | $100.7M | 9.30% |
| 7 | Aerovate Therapeutics, Inc. | 008064107 | 2,039,249 | $60.3M | 5.57% |
| 8 | Q32 Bio, Inc. | QTTB | 2,092,106 | $35.6M | 3.29% |
| 9 | Generation Bio, Co. | 37148K100 | 8,279,484 | $33.7M | 3.11% |
| 10 | Vigil Neuroscience, Inc. | 92673K108 | 5,836,874 | $19.9M | 1.84% |
| 11 | Replimune Group, Inc. | REPL | 2,098,300 | $17.1M | 1.58% |
| 12 | Ikena Oncology, Inc. | 45175G108 | 5,018,178 | $7.1M | 0.66% |
| 13 | AvroBio, Inc. | 05455M100 | 4,541,381 | $5.8M | 0.54% |
| 14 | Dianthus Therapeutics, Inc. | DNTH | 186,979 | $5.6M | 0.52% |
| 15 | Xilio Therapeutics, Inc. | XLO | 992,912 | $1.1M | 0.10% |
| 16 | Spero Therapeutics, Inc. | SPRO | 607,613 | $1.0M | 0.10% |